Merck KGaA, the German science and technology company headquartered in Darmstadt, on Wednesday announced the rebranding of its pharmaceutical subsidiary in Korea from Merck Biopharma Korea to Merck Healthcare Korea.

The name change reflects the company's strategic shift to reinforce its identity as a healthcare-focused business under the global vision of “Sparking Discovery, Elevating Humanity.”

The renaming aligns with Merck's international brand strategy and is aimed at clearly positioning the subsidiary as a patient-centered healthcare division. Merck Healthcare Korea plans to enhance its engagement with Korea’s unmet medical needs by expanding access to innovative therapies, digital healthcare solutions, and integrated patient support services.

“Renaming the business to Merck Healthcare Korea is a deliberate step to reflect the patient-centric philosophy of our global healthcare division,” Merck Healthcare Korea General Manager Christoph Hamann said. “We remain committed to delivering innovative treatments and accelerating access to new medicines, especially in areas with significant unmet needs such as immunotherapy, neuroimmunology, infertility, and endocrine disorders.”

Globally, Merck operates in 65 countries and employs more than 62,000 people across three core business sectors -- Healthcare, Life Science, and Electronics.

In regions outside of the U.S. and Canada, Merck retains exclusive rights to its corporate name and brand. In North America, however, the company’s operations are conducted under different legal entities -- EMD Serono for healthcare, MilliporeSigma for life sciences, and EMD Electronics for electronics.